India's Sun Pharmaceuticals announces approval of Winlevi in Australia for acne treatment
India, March 20 -- based Sun Pharmaceutical Industries has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi (clascoterone cream 1%). Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
As stated by Hellen de Kloet, Business Head - Western Europe, Australia and New Zealand, Sun Pharma, "Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi's novel mechanism of action will be a welcome addition to the physician's toolkit while treating acne."
Diana Harbort, President of the Dermatology Division of Cosmo, said, "We are very pleased that Winlevi will soon be availab...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.